Navigation Links
ISTA Pharmaceuticals Initiates Phase 2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
Date:12/14/2010

IRVINE, Calif., Dec. 14, 2010 /PRNewswire/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it has initiated a Phase 2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group environmental study will evaluate the safety and efficacy of bepotastine besilate, dosed twice daily, in patients presenting with allergic rhinitis caused by one of the most potent seasonal allergy triggers, Mountain Cedar pollen.

ISTA expects to enroll approximately 600 patients in Texas who will be treated with either bepotastine besilate nasal spray or placebo for two weeks. Patients will grade both individual nasal and ocular symptoms on a daily basis.

"This nasal spray drug candidate represents an expansion of our focus in prescription allergy treatments, which currently includes BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% for the treatment of ocular itching associated with allergic conjunctivitis,"  commented Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA. "The results from our Phase 1/2 clinical study of bepotastine besilate nasal spray, announced in October 2010, showed a robust patient response to the nasal spray without serious side effects.  We expect to have preliminary data from this Phase 2 Mountain Cedar pollen study during the first half of 2011."

ISTA submitted the Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for bepotastine besilate nasal spray in November 2010.

ABOUT THE ALLERGIC RHINITIS MARKET

According to the American Academy of Allergy Asthma & Immunology (AAAAI), approximately 60 million Americans are affected by allergic rhinitis, an inflammation of t
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders
2. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
3. Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders
4. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
5. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
6. Access Pharmaceuticals Reports Significant Third Party Payer Reimbursement Progress for MuGard
7. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
8. Lotus Pharmaceuticals Announces Update on Land in Inner Mongolia
9. Reportlinker Adds Global Generic Pharmaceuticals Industry Report
10. Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study
11. Data from Phase 2 Study of Alder Biopharmaceuticals Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Reported at American Association for Cancer Research ... -- Favrille,Inc. , a biopharmaceutical company developing ... announced,results from a new study showing enhanced ... key component in the Company's,Id/KLH immunotherapy product ...
... Origin May Be Useful in Cancer Treatment,Decisions , ... Inc.,(NASDAQ: MYGN) (<a target="_blank" href=,"http://www.myriad.com/">www.myriad.com ) announced today ... might be used to,determine the original location of ... the annual meeting of the American Association,for Cancer ...
Cached Medicine Technology:Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma 2Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma 3Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma 4Myriad Genetics Presents Tumor Origin Technology at AACR 2Myriad Genetics Presents Tumor Origin Technology at AACR 3
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... 16, 2014) The cause of neuronal death in ... proposes that neurons may be mistaken for foreign invaders ... to the way autoimmune diseases like type I diabetes, ... The study was published April 16, 2014, in ... likely controversial, idea in Parkinson,s disease; but if true, ...
(Date:4/17/2014)... Alliance, a nonprofit organization that focuses on conservation and ... examining the current state of knowledge of the deadly ... global surveillance strategies to combat the emergence of infectious ... West Africa that has claimed the lives of 122 ... According to the World Health Organization (WHO), the deadly ...
(Date:4/17/2014)... 2014) Population Council scientists and their partners have found ... can prevent the transmission of multiple sexually transmitted infections ... HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus ... that the gel is effective against multiple strains of ... vagina against all three viruses of at least eight ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... teenagers have a lot in common: Sugary soda. Fast-food ... Low-income teenagers are almost three times more likely to ... to new research from the UCLA Center for Health ... 21 percent of teenagers living in low-income families are ...
... Calif., Dec. 10 ThermoGenesis,Corp. (Nasdaq: KOOL ... process and store adult stem cells, said today that ... (POC) products under the,Vantus brand. Unveiling of the ... 54th Annual Convention of the American Association of Equine,Practitioners ...
... HONOLULU, Dec. 10 Hoana Medical announced today that ... at the Institute for Healthcare Improvement (IHI) premier event ... leaders in hospital,safety. , ... conjunction with the,IHI event, to introduce its LifeGurney system, ...
... prostate cancer patients with drugs that block hormonal activity ... from cardiovascular disease, according to a study led by ... report from members of the same study team found ... risk of diabetes and heart disease, the current study ...
... A group of nutritionists from Extenso, the Universit de ... chefs from the Institut de tourisme et d,htellerie du ... and early childhood centres. The goal is to help ... for kids. , The nutrition team will provide its ...
... Ga., Dec. 10 Joe Jurevicius, Tom Brady, ... few months the list,of top professional football players ... read as a who,s who of the National ... infections is healthcare facilities,where athletes are undergoing surgeries, ...
Cached Medicine News:Health News:Obesity among state's low-income teens nearly triple that of more affluent peers 2Health News:ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention 2Health News:ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention 3Health News:ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention 4Health News:Hoana Medical to Present at the National Forum on Quality Improvement in Health Care 2Health News:Hoana Medical to Present at the National Forum on Quality Improvement in Health Care 3Health News:Hoana Medical to Present at the National Forum on Quality Improvement in Health Care 4Health News:Hormone therapy for prostate cancer does not appear to increase cardiac deaths 2Health News:Hormone therapy for prostate cancer does not appear to increase cardiac deaths 3Health News:New partnership to foster healthier food habits in early childhood 2Health News:Staph Infections Hit Professional Football Hard 2Health News:Staph Infections Hit Professional Football Hard 3
Pocket-sized instrument with direct illumination. Avaliable in black, green or blue....
Provides 30% more illumination, high light output for true tissue. Wide-angle viewing lens, sealed system for pneumatic otoscopy....
Provides 30% more magnification and twice the field of view. Adjustable focus, with insufflator bulb....
... delivers power and reliability with proprietary ... Diode side-pumping technology drives 2.5 W ... Spectra system, and active resonator temperature ... system reliability from your first treatment ...
Medicine Products: